Avalyn Pharma Inc. Operating Expenses
Avalyn Pharma Inc. (AVLN) reported Operating Expenses of $31.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Avalyn Pharma Inc. operating expenses for the quarter ending 2026-06-30 was $31.29M, a 43.68% increase year-over-year.
- Avalyn Pharma Inc. operating expenses for the quarter ending 2026-03-31 was $27.91M, a 49.12% increase year-over-year.
- Avalyn Pharma Inc. operating expenses for the quarter ending 2025-06-30 was $21.78M.
- Avalyn Pharma Inc. operating expenses for the quarter ending 2025-03-31 was $18.72M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month |
|---|---|---|
| 2026-06-30 | $31.29M 10-Q · filed 2026-08-12 | $59.20M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $27.91M 10-Q · filed 2026-06-03 | |
| 2025-06-30 | $21.78M 10-Q · filed 2026-08-12 | $40.49M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $18.72M 10-Q · filed 2026-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |